Knowledge of genetics improves uncertain medication
Roughly 100,000 Swedes are under treatment with the blood-thinning drug Waran. Patients evince varying sensitivity to Waran, which makes the initiation of treatment a risky balancing act between hemorrhaging and clotting. Researchers at Uppsala University have developed a model for calculating the appropriate dose before treatment starts. The study appears in New England Journal of Medicine.